Associated Papers
Human BRCA pathogenic variants were originated during recent human history.
Li J et al.
Life Science Alliance, 2022
Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy.
Papi L et al.
Breast Cancer Research and Treatment, 2009
Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families.
Hartikainen JM et al.
Clinical Genetics, 2007
Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families.
Eerola H et al.
Breast Cancer Research : Bcr, 2005
BRCA1 and BRCA2 mutations have no major role in predisposition to prostate cancer in Finland.
Ikonen T et al.
Journal of Medical Genetics, 2003
The western Swedish BRCA1 founder mutation 3171ins5; a 3.7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation.
Bergman A et al.
European Journal of Human Genetics : Ejhg, 2001
Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: a relative survival analysis from Finland.
Eerola H et al.
International Journal of Cancer, 2001
BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients.
Sarantaus L et al.
European Journal of Human Genetics : Ejhg, 2001
Involvement of BRCA1 and BRCA2 in breast cancer in a western Finnish sub-population.
Pääkkönen K et al.
Genetic Epidemiology, 2001
Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland.
Sarantaus L et al.
European Journal of Human Genetics : Ejhg, 2000
Denaturing high-performance liquid chromatography detects reliably BRCA1 and BRCA2 mutations.
Wagner T et al.
Genomics, 1999
Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes.
Vehmanen P et al.
Human Molecular Genetics, 1997
Select a paper to view details